查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
影像導引藥物傳輸市場 - 全球及區域分析：按技術類型、應用、最終用戶和區域 - 分析與預測（2025-2035年）
市場調查報告書
商品編碼
1811795

影像導引藥物傳輸市場 - 全球及區域分析：按技術類型、應用、最終用戶和區域 - 分析與預測（2025-2035年）

Image-Guided Drug Delivery Market - A Global and Regional Analysis: Focus on Technology Type, Application, End User, and Regional Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 128 Pages | 商品交期: 1-5個工作天內

價格

影像導引藥物傳遞是應用先進、精確和微創技術將治療劑直接輸送到目標疾病部位，例如腫瘤或神經區域。

這個創新領域代表了現代醫學的模式轉移，超越了傳統的全身性治療，轉向更安全、更局部、特異性病人的治療。透過將導管和插管等專用藥物輸送系統與MRI、CT和超音波成像平台相結合，並輔以機器人技術和人工智慧導航，影像引導藥物輸送使臨床醫生能夠以卓越的精度和可控性實施基因治療、化療和細胞療法。這種方法可以提高治療效果，最大限度地降低全身毒性，縮短恢復時間，並最佳化醫療資源，使影像導引藥物輸送成為下一代精準醫療的基石。

主要市場統計資料
預測期 2025-2035
2025年評估 6580萬美元
2035年的預測 9.83億美元
年複合成長率 31.04%

市場介紹

全球影像導引藥物輸送市場可望大幅成長，預計到2035年將達到 9.83億美元。在導管輸液系統、多孔套管和影像引導導航平台的支援下，IGDD 整合了先進的影像處理、機器人和人工智慧，以卓越的精度提供局部治療，最大限度地降低全身毒性，並改善患者預後。

影像引導藥物傳輸代表了現代醫學的模式轉移，它結合了精準的診斷成像、可控輸注和即時監測，擴大了標靶治療的可及性。 ClearPoint Neuro 的SmartFlow 套管（美國首個獲得 FDA 全新批准的腦內基因治療設備）以及 TriSalus Life Sciences 的TriNav FLX 輸注系統的商業化等重要里程碑，都體現了這種顛覆性方法。同樣，像Koninklijke Philips NV的EmboGuide 和通用電氣醫療的FlightPlan for Liver 這樣的軟體主導導航平台，也支援複雜腫瘤和神經外科手術朝向標準化和可重複性邁進。

北美、歐洲和日本有利的監管和償付框架，以及公共和私營部門在混合手術室、影像基礎設施和介入醫師培訓方面不斷增加的投資，進一步支持了市場擴張。北美、歐洲和亞太國家擴大醫院容量並培養創新中心，而隨著精準醫療的加速應用，印度、巴西和東南亞等新興市場提供了尚未開發的成長潛力。

基於人工智慧的輸注計畫、相容MRI的手術機器人以及多模態成像等創新技術提升給藥準確性和長期治療效果。雖然腫瘤學仍然是主要的應用領域，但神經病學迅速發展，尤其是在神經膠母細胞瘤、帕金森氏症和AADC缺乏症等疾病的基因和細胞治療方面。胃腸道和循環系統疾病領域的更廣泛應用也開始拓展影像導引藥物傳遞技術的覆蓋範圍。

儘管動力強勁，挑戰依然存在，包括高昂的實施成本、工作流程整合的障礙以及中低收入社區的醫療資源取得不均衡。然而，隨著支付方的支持日益增多，加上產學研合作的推進，這些障礙透過加快臨床檢驗和降低應用門檻來穩步克服。

ClearPoint Neuro, Inc.、TriSalus Life Sciences, Inc.、RenovoRxKoninklijke Philips NV、GE HealthCare和 AiM Medical Robotics 等領先公司塑造競爭格局，開發First-in-Class的設備，積累強力的臨床證據，並在腫瘤學和神經病學領域推行競爭格局。隨著醫療保健越來越重視精準醫療、微創療法和以患者為中心的護理，影像引導給藥技術正處於治療創新的前沿，有望重新定義治療模式，改善全球患者的治療效果。

對產業的影響

影像導引藥物傳遞技術重塑腫瘤學和神經病學治療，它能夠以微創方式精準引導先進療法的給藥。基於導管的注射平台，例如 ClearPoint Neuro 的SmartFlow 套管和 TriSalus Life Sciences 的TriNav FLX，重新定義了程序的精準度，使藥物和基因療法能夠直接作用於目標腦區和固態腫瘤。透過突破血腦障壁等障礙並確保局部藥物滲透，IGDD 技術提高了療效，降低了全身毒性，並最大限度地縮短了住院時間，使其成為下一代個人化醫療的關鍵推動者。

除了單一手術之外，影像導引給藥推動整個手術生態系統和臨床工作流程的創新。 MRI/CT導引導航平台、機器人系統和AI輔助注射計畫工具的整合，實現藥物定位的標準化，並實現即時治療監測，拓展了難以觸及的腫瘤和中樞神經系統疾病的治療方案。這些平台簡化臨床決策，減少手術差異，並提高不同中心治療的可重複性。

同時，設備創新者、製藥公司和學術研究中心之間的策略聯盟加速影像導引藥物輸送在細胞和基因治療臨床試驗的應用，目前已有60多家生物製藥合作夥伴利用ClearPoint Neuro的系統進行中樞神經系統標靶輸送。監管支持的途徑，例如SmartFlow獲得FDA的從頭批准和歐盟的MDR認證，加上精準注射技術償付額度的提高，推動其商業性發展。

從全系統層面來看，影像導引給藥技術透過擴大先進治療手段的可近性來提升醫療體系的韌性，尤其是在三級醫院和癌症中心。對混合手術室、介入神經放射學手術室和數影像處理基礎設施的投資，推動這些技術的擴充性；與Koninklijke Philips NV、GE HealthCare和創新生物技術公司等全球領先企業的合作，推動影像引導給藥技術（IGDD）走向主流應用。總而言之，這些進步重新定義醫療服務，改善病患預後，並鞏固腫瘤和神經內科精準醫療的基礎。

市場區隔

細分 1：依技術類型

  • 藥物輸送系統
  • 影像引導平台

藥物輸送系統（DDS）將繼續成為全球影像導引藥物輸送市場中依技術類型分類的領先細分市場，到2024年將佔據 71.79%的市場佔有率，預計2025年至2035年的年複合成長率將達到 30.87%。套管針、多孔導管和壓力輸注系統等關鍵細分市場因其直接的治療作用、經過驗證的臨床效用以及克服血腦障壁和腫瘤內藥物滲透等挑戰的能力而貢獻最大。 DDS 佔據主導地位，因為它們在實現先進療法的靶向傳遞、高效治療以及在腫瘤學和神經病學試驗中的廣泛應用方面發揮著重要作用。

相較之下，ClearPoint Navigation、Philips EmboGuide 和 GE FlightPlan for Liver 等影像引導平台透過改進供血血管檢測、提高瞄準精度和標準化程序，經歷快速成長。目前，IGP 市場規模較小，但隨著臨床工作流程需要更先進的影像整合，其佔有率預計將擴大。

細分2：依應用

  • 腫瘤學
  • 神經
  • 其他

依應用分類，全球影像導引藥物傳輸市場由腫瘤學領域主導，2024年佔 76.44%的市場。受全球癌症發生率上升以及肝癌、胰腺癌和頭頸癌等癌症對精準醫療的需求推動，預計腫瘤學領域將保持主導地位直至2035年。動脈內輸注平台和栓塞軟體已證明能夠將局部藥物濃度提高 100 倍（與靜脈途徑相比），減少全身副作用並強化腫瘤學作為關鍵驅動力。神經病學是成長最快的領域，由 FDA 和 CE 認證的技術提供支持，例如 SmartFlow 套管、神經輸注和多孔導管，這些技術可實現針對中樞神經系統的靶向藥物輸送，用於治療膠質母細胞瘤、帕金森氏症和 AADC 缺乏症等疾病。

細分 3：依最終用戶

  • 醫院
  • 製藥和生物技術公司
  • 委外研發機構（CRO）
  • 科學研究院所及大學

從終端用戶來看，全球影像導引給藥市場將由醫院主導，到2024年將佔91.30%的市場佔有率。配備混合手術室、先進影像設備以及專業神經外科和腫瘤科團隊的醫院，將繼續成為影像導引給藥系統（IGDD）應用的主要樞紐。醫院能夠執行顱內注射和定向腫瘤治療等大量複雜手術，這增強了其優勢，隨著下一代療法在臨床實踐中的應用，預計其應用將進一步擴大。

細分4：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 澳洲
    • 韓國
    • 其他
  • 其他地區

受中國高疾病負擔、國內創新和影像基礎設施建設的推動，亞太地區影像引導給藥市場不斷擴張。日本和韓國憑藉強大的保險支持以及先進的腫瘤和神經病學中心，推動該技術的普及；而印度龐大但滲透率較低的市場則因需求成長和本土創新而蓬勃發展。澳洲受益於強大的保險償付體系和私人應用，而新加坡、香港和馬來西亞則在都市區提供了利基市場機會。相較之下，印尼、越南和菲律賓則面臨基礎設施和資金籌措的挑戰。總體而言，亞太地區的成長將取決於創新、可負擔性和公平的可近性。

影像導引藥物傳輸市場的最新趨勢

  • 2025年 8月，ClearPoint Neuro, Inc. 報告指出，該公司使用 FDA 批准的SmartFlow Neuro Cannula 在美國首次商業性交付 KEBILIDI（AADC 缺乏症基因療法），標誌著臨床應用邁出了關鍵一步。
  • 2025年6月，TriSalus Life Sciences, Inc. 推出了 TriNavFLX 輸液系統，這是其 PEDD（壓力驅動藥物輸送）系列的新產品。該系統的遠端長度是先前型號的兩倍，且更加靈活，使其能夠在曲折的血管中平穩導航。桌上型測試表明，與標準 TriNav 相比，導航力降低了 28%。
  • 2025年5月，ClearPoint Neuro, Inc.與Oberland Capital簽訂了高達1.1億美元的結構化融資協議，其中包括票據融資和股權部分。
  • 2025年4月，約翰霍普金斯醫院加入了RenovoRx的TIGeR-PaC試驗，登錄局部晚期胰臟癌（LAPC）患者。本試驗將評估RenovoRx的RenovoCath裝置引導的動脈Gemcitabine（IAG）注射與標準靜脈化療比較。此次加入將增強該試驗的有效性，該試驗的目標是到2025年完成全部患者入組。
  • 2025年4月，ClearPoint Neuro, Inc. 發布了 ClearPoint 導航軟體 3.0 版，這是第一個專為標準手術室設計的完整端對端 ClearPoint 導航解決方案。它引進了全新的iCT 導引工作流程，無需 MRI 基礎設施即可實現高精度腦部導航。

需求 - 促進因素、挑戰、機會

市場促進因素

  • 個人化醫療需求不斷成長

個人化醫療日益成長的需求正迅速推動影像引導藥物輸送市場的發展，強調了根據個別患者情況量身定做精準標靶治療的必要性。在腫瘤學和神經病學等領域，個人化醫療根據基因和疾病特異性特徵調整治療方案，以確保最有效的治療結果，同時最大限度地減少副作用。影像引導藥物傳遞技術在這一轉變中發揮關鍵作用，它能夠將藥物精確、局部靶向到特定的身體部位，提高治療性介入的精準度。2024年發表在《藥理學研究》上的一項題為「藥物傳遞系統中的生技藥品、治療診斷學和個人化醫療」的研究強調了影像引導藥物傳遞在治療診斷學領域的作用，而治療診斷學是個人化醫療的關鍵組成部分。這種方法利用先進的影像技術精確引導和監測治療劑，確保藥物在目標疾病部位的精確定位。

透過最大限度地減少脫靶效應，這項技術顯著改善了治療效果。此外，治療方案可即時調整，最佳化藥物輸送，確保精準劑量到達正確部位。這種精準性在前列腺癌和神經退化性疾病等領域尤其重要，精準藥物標靶可顯著改善患者預後。

  • 慢性病盛行率上升

市場限制

  • 設備購置成本高

影像導引給藥裝置的高成本仍然是這項創新技術廣泛應用和市場成長的一大障礙，尤其是在中低收入國家。這些系統高度依賴先進的影像技術，例如核磁共振成像（MRI）、CT 和螢光透視，這些技術對於手術和給藥過程中的精確導航非常重要。然而，這些技術的經濟負擔也相當沉重。例如，核磁共振造影系統的價格在 13萬至 70萬美元之間，此外還有持續的維護、軟體更新和專業人員培訓成本。高昂的初始成本和持續的營運成本對醫院構成了重大障礙，尤其是在資源受限的環境中，由於醫療預算有限，難以證明投資的合理性。

因此，此財務障礙不僅限制了影像導引給藥系統在臨床環境中的應用，也阻礙了整體市場的擴張。新興國家中預算有限的小型醫療保健機構通常無力投資此類技術。這導致影像導引給藥技術集中在少數資金充足的醫院，限制了其廣泛應用及其對醫療資源匱乏地區患者照護的潛在影響。因此，這些地區的患者無法享受更精準、更有針對性的給藥服務，而這種服務在癌症治療和需要高精度的專科醫療程序中尤其有用。

市場機會

  • 將人工智慧融入影像引導藥物輸送

影像導引藥物傳遞系統與人工智慧（AI）的結合已成為癌症治療的一項革命性進步，為藥物傳遞和監測的精確度、準確度和效率帶來了可喜的提升。 AI 加速了影像分析過程，能夠識別醫學掃描中的細微模式，最佳化藥物向腫瘤部位的輸送。這項創新使臨床醫生能夠以前所未有的精確度瞄準腫瘤，確保適量的藥物到達腫瘤，同時最大限度地減少對健康組織的暴露。即時監測是癌症個人化治療的關鍵組成部分，而 AI 能夠持續追蹤體內藥物和奈米顆粒的行為，大大增強了即時監測的能力。 AI 演算法監測藥物分佈並動態調整藥物傳遞過程，以更可靠地瞄準癌細胞。透過提供這種程度的監測，AI 有助於提高治療的精確度和結果，為臨床醫生提供做出更明智決策所需的工具。 AI 的影響不僅限於增強影像和監測，還擴展到個人化治療計劃。

市場趨勢

成像與藥物傳輸的整合

影像與標靶給藥的融合是現代醫學的關鍵趨勢，從根本上重塑了神經病學和腫瘤學的治療方法。這項模式轉移由多項關鍵進展的匯聚推動，包括重要的監管里程碑、不斷擴大的臨床應用、創新新設備的推出以及強勁的市場發展動力。這種融合對影像引導給藥市場產生了深遠的影響，使其迅速從以研究為重點的小眾領域擴展至主流臨床應用。這一轉變得益於美國食品藥物管理局（FDA）對ClearPoint Neuro, Inc.的SmartFlow Neuro Cannula等設備的重新核准，這為類似技術檢驗了清晰的監管途徑，降低了投資者風險並加速了商業化進程。在臨床層面，即時影像和專用導管的使用提供了前所未有的精準度，確保更高濃度的治療藥物到達目標部位，同時保護健康組織。

這不僅提高了治療效果並降低了毒性，還能創造出標準化、可重複的工作流程，進而提高醫院的效率和成本效益。市場上湧現大量新型專用設備，例如 RenovoRx 的RenovoCath 和 TriSalus Life Sciences 的TriNav FLX，推動了靶向腫瘤治療和中樞神經系統給藥等高成長領域的發展。最終，專用給藥設備與影像導引導航的結合將創造新的治療標準，減少併發症，提高手術成功率，並改善這些重要治療領域的患者預後。

成長/行銷策略：透過提供全面的市場分析和識別關鍵的成長機會，公司能夠獲得制定有針對性的行銷策略和有效擴大其市場佔有率的知識。

競爭策略：透過對競爭格局的徹底分析，了解競爭對手的優勢和劣勢，並幫助制定有效的策略以在市場上獲得競爭優勢。

監管和合規策略：提供有關不斷發展的法律規範、核准和行業指南的最新資訊，以使公司能夠保持合規並加快新型圖像引導藥物輸送的市場進入。

投資和業務擴大策略：透過分析市場趨勢、資金籌措模式和合作機會，幫助公司做出明智的投資決策並確定業務成長的潛在併購機會。

公司簡介的選擇是基於對公司覆蓋範圍、產品系列、市場滲透率的分析以及從主要專家收集的意見。

影像導引藥物傳輸市場的主要企業包括全球醫療設備和影像處理公司，它們為腫瘤學和神經病學領域提供廣泛的藥物傳輸系統和影像引導平台。 ClearPoint Neuro, Inc.、Koninklijke Philips N.V.、GE Healthcare等老牌企業憑藉其用於介入腫瘤學和中樞神經系統治療的整合式 MRI 導引導航、輸液套管和血管映射軟體產品組合佔據主導地位。

創新企業開發多孔導管、壓力驅動輸液系統和人工智慧輔助導航軟體，以提高輸送準確性和治療效果。 TriSalus Life Sciences 和 RenovoRx 等公司率先推出基於導管的腫瘤學平台，而 AiM Medical Robotics 等公司則開發用於神經外科的兼容 MRI 的手術機器人。 Neurochase 和 Infusion Therapeutics 等新興企業推出用於直接腦部輸液的新型對流增強輸送系統。

新興企業和區域性公司也貢獻經濟高效的注射技術、可攜式導航工具以及專業的藥物-器械組合，以滿足新興市場尚未滿足的需求。這些公司共同推動創新，擴大臨床可及性，並將影像引導藥物輸送確立為精準引導、微創治療傳遞的基石。

該市場上知名的知名公司包括：

  • ClearPoint Neuro, Inc.
  • TriSalus Life Sciences, Inc.
  • GE Healthcare
  • Koninklijke Philips NV
  • RenovoRx Inc.

目錄

執行摘要

第1章 市場：產業展望

  • 競爭格局
  • 產業展望
  • 市場動態

第2章 技術

  • 概述
  • 藥物輸送系統
  • 影像引導平台

第3章 應用

  • 概述
  • 腫瘤學
  • 神經病學
  • 其他

第4章 最終用戶

  • 概述
  • 醫院
  • 科學研究機構和大學
  • 製藥和生物技術公司
  • CRO

第5章 區域

  • 區域摘要
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 市場-公司簡介

  • 公司簡介
    • ClearPoint Neuro, Inc.
    • AiM Medical Robotics
    • TriSalus Life Sciences
    • RenovoRx Inc.
    • Renishaw plc.
    • Occam Design
    • Infuseon Therapeutics Inc
    • Neurochase
    • GE HealthCare
    • Koninklijke Philips NV

第7章 調查方法

Product Code: BHL3241SA

This report can be delivered within 1 working day.

Introduction of Image-Guided Drug Delivery

Image-Guided Drug Delivery applies advanced, precision-driven, minimally invasive techniques to deliver therapeutics directly to targeted disease sites, including tumors and neurological regions. This innovative field represents a paradigm shift in modern medicine, moving beyond conventional systemic therapies toward safer, more localized, and patient-specific interventions. By combining specialized drug delivery systems such as catheters and cannulae with MRI, CT, and ultrasound-based imaging platforms, augmented by robotics and AI-driven navigation, image-guided drug delivery enables clinicians to administer gene therapies, chemotherapeutics, and cell-based treatments with exceptional accuracy and control. This approach improves therapeutic efficacy, minimizes systemic toxicity, shortens recovery times, and optimizes healthcare resources, positioning image-guided drug delivery as a cornerstone of next-generation precision medicine.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$65.8 Million
2035 Forecast$983.0 Million
CAGR31.04%

Market Introduction

The global image-guided drug delivery market is expected to witness significant growth, projected to reach $983.0 million by 2035, driven by the escalating global burden of cancer, neurological disorders, and other chronic diseases that demand safer, more precise, and less invasive therapeutic approaches. Anchored in catheter-based infusion systems, multiport cannulae, and image-guided navigation platforms, IGDD integrates advanced imaging, robotics, and AI to deliver localized therapies with superior accuracy, minimized systemic toxicity, and improved patient outcomes.

Image-guided drug delivery represents a paradigm shift in modern medicine, combining imaging precision, controlled infusion, and real-time monitoring to expand access to targeted therapies. Key milestones, such as the FDA De Novo clearance of ClearPoint Neuro's SmartFlow Cannula, the first U.S.-approved device for intracerebral gene therapy-and the commercial launch of TriSalus Life Sciences' TriNav FLX infusion system, have validated these disruptive approaches. Similarly, software-driven navigation platforms such as Koninklijke Philips' EmboGuide and GE HealthCare's FlightPlan for Liver underscore the move toward standardization and reproducibility in complex oncology and neurology procedures.

Market expansion is further supported by favorable regulatory and reimbursement frameworks in North America, Europe, and Japan, coupled with increasing investments from the public and private sectors in hybrid operating suites, imaging infrastructure, and training for interventional specialists. Countries across North America, Europe, and Asia-Pacific are scaling hospital capacity and fostering innovation hubs, while emerging markets such as India, Brazil, and Southeast Asia present untapped potential for growth as precision medicine adoption accelerates.

Technological convergence is a key accelerator, with innovations in AI-assisted infusion planning, MRI-compatible surgical robotics, and multimodal imaging enhancing both delivery accuracy and long-term therapeutic outcomes. While oncology remains the dominant application, neurology is rapidly expanding, particularly in gene and cell therapy delivery for conditions such as glioblastoma, Parkinson's disease, and AADC deficiency. Broader applications in gastrointestinal and cardiovascular disorders are also beginning to extend the scope of image-guided drug delivery technologies.

Despite strong momentum, challenges such as high acquisition costs, workflow integration barriers, and uneven access in low- and middle-income regions remain. However, growing payer support, coupled with industry-academic-biopharma collaborations, is steadily overcoming these hurdles by accelerating clinical validation and lowering barriers to adoption.

Leading players such as ClearPoint Neuro, Inc., TriSalus Life Sciences, Inc., RenovoRx, Koninklijke Philips N.V., GE HealthCare, and AiM Medical Robotics are shaping the competitive landscape, advancing first-in-class devices, building robust clinical evidence, and pursuing commercialization strategies across oncology and neurology. As healthcare increasingly emphasizes precision medicine, minimally invasive delivery, and patient-centric care, image-guided drug delivery is positioned at the forefront of therapeutic innovation, set to redefine treatment paradigms and improve outcomes for patients worldwide.

Industrial Impact

Image-guided drug delivery is reshaping therapeutic care in oncology and neurology by enabling minimally invasive, precision-guided administration of advanced treatments. Catheter-based infusion platforms such as ClearPoint Neuro's SmartFlow Cannula and TriSalus Life Sciences' TriNav FLX have redefined procedural accuracy, allowing direct drug and gene therapy delivery into targeted brain regions or solid tumors. By overcoming barriers such as the blood-brain barrier and ensuring localized drug penetration, IGDD technologies are improving efficacy, reducing systemic toxicity, and minimizing hospital stays-positioning them as critical enablers of next-generation personalized medicine.

Beyond individual procedures, image-guided drug delivery is fostering innovation across procedural ecosystems and clinical workflows. Integration of MRI/CT-guided navigation platforms ,robotic systems, and AI-assisted infusion planning tools is standardizing drug placement, enabling real-time therapy monitoring, and expanding treatment options for hard-to-reach tumors and CNS disorders. These platforms streamline clinical decision-making, reduce procedural variability, and make therapies more reproducible across institutions.

Simultaneously, strategic collaborations between device innovators, pharmaceutical companies, and academic research centers are accelerating the adoption of image-guided drug delivery in cell and gene therapy trials, with >60 biopharma partners already leveraging ClearPoint Neuro's systems for CNS-targeted delivery. Supportive regulatory pathways, such as the FDA's De Novo clearance of SmartFlow and EU MDR certifications, coupled with increasing reimbursement for precision infusion procedures, are driving commercial momentum.

At a system-wide level, Image-guided drug delivery is enhancing healthcare resilience by broadening access to advanced therapies, particularly in tertiary-care hospitals and cancer centers. Investments in hybrid ORs, neuro-interventional suites, and digital imaging infrastructure are enabling scalability of these technologies, while partnerships with global leaders such as Koninklijke Philips N.V., GE HealthCare, and innovative biotech firms are pushing IGDD toward mainstream adoption. Collectively, these advancements are redefining treatment delivery, improving patient outcomes, and strengthening the foundations of precision therapy in oncology and neurology.

Market Segmentation:

Segmentation 1: By Technology Type

  • Drug-Delivery Systems
  • Image-Guided Platforms

Drug-Delivery Systems (DDS) remain the leading segment by technology type in the global image-guided drug delivery market, holding 71.79% market share in 2024, with a projected CAGR of 30.87% during 2025-2035. Key subsegmentssuch as cannulae, multiport catheters, and pressure-enabled infusion systems drive the largest contributions due to their direct therapeutic role, proven clinical utility, and ability to overcome challenges such as the blood-brain barrier or intratumoral drug penetration. DDS dominate because of their essential role in enabling targeted delivery of advanced therapies, higher efficacy, and wider adoption in both oncology and neurology trials.

In contrast, Image-Guided Platforms including ClearPoint Navigation, Philips EmboGuide, and GE FlightPlan for Liver are growing rapidly as they improve feeder-vessel detection, enhance targeting accuracy, and standardize procedures. While smaller today, IGPs are expected to capture increasing share as clinical workflows demand greater imaging integration.

Segmentation 2: By Application

  • Oncology
  • Neurology
  • Others

Based on application, the global image-guided drug delivery market was led by the Oncology segment, which accounted for 76.44% share in 2024. Oncology is projected to maintain dominance through 2035 due to the rising global cancer burden and the demand for precision therapies in hepatic, pancreatic, and head & neck cancers. Intra-arterial infusion platforms and embolization software have demonstrated the ability to improve local drug concentration by up to 100X compared to IV routes, reducing systemic side effects and reinforcing oncology as the primary growth driver. Neurology is the fastest-growing segment, supported by FDA and CE-cleared technologies such as SmartFlow Cannula, neuroinfuse, and multiport catheters that enable targeted CNS delivery for conditions like glioblastoma, Parkinson's, and AADC deficiency.

Segmentation 3: By End User

  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Research Institutes & Universities

Based on end user, the global image-guided drug delivery market was led by the Hospitals segment, which held a 91.30% share in 2024. Hospitals remain the primary hubs for IGDD adoption, equipped with hybrid operating suites, advanced imaging modalities, and specialized neurosurgical and oncology teams. Their ability to perform high-volume, complex procedures such as intracranial infusions and liver-directed oncology therapies supports their dominance, with adoption expected to grow as more next-generation therapies enter clinical practice.

Segmentation 4: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

The Image-Guided Drug Delivery market in the Asia-Pacific region is expanding, led by China's high disease burden, domestic innovation, and growing imaging infrastructure. Japan and South Korea drive adoption through strong insurance support and advanced oncology and neurology centers, while India's vast, underpenetrated market is gaining momentum with rising demand and local innovation. Australia benefits from strong reimbursement and private adoption, whereas Singapore, Hong Kong, and Malaysia offer niche urban opportunities. In contrast, Indonesia, Vietnam, and the Philippines face infrastructure and funding challenges. Overall, growth in APAC hinges on innovation, affordability, and equitable access.

Recent Developments in the Image-Guided Drug Delivery Market

  • In August 2025, ClearPoint Neuro, Inc. reported the first-ever commercial delivery of KEBILIDI (AADC deficiency gene therapy) in the U.S. using its FDA-authorized SmartFlow Neuro Cannula, marking a pivotal step in clinical implementation.
  • In June 2025, TriSalus Life Sciences, Inc. rolled out the TriNavFLX Infusion System, a new addition to its Pressure Enabled Drug Delivery (PEDD) line. The system's distal end is twice as long and more flexible than previous models, enabling smooth navigation through tortuous vessels. In benchtop testing, it reduced navigation force by 28% compared to the standard TriNav.
  • In May 2025, ClearPoint Neuro, Inc. entered into a structured financing agreement with Oberland Capital for up to $110 million, including note financing and equity components.
  • In April 2025, Johns Hopkins Medicine joined RenovoRx's TIGeR-PaC trial, enrolling patients with locally advanced pancreatic cancer (LAPC). The trial evaluates RenovoRx's intra-arterial gemcitabine (IAG) delivery via the RenovoCath device, comparing it to standard intravenous chemotherapy. This addition strengthens the trial, aiming for full enrollment by 2025.
  • In April 2025, ClearPoint Neuro, Inc. released ClearPoint Navigation Software Version 3.0, the first full end-to-end ClearPoint navigation solution specifically designed for standard operating rooms. It introduces a new iCT-guided workflow, enabling high-precision brain navigation without requiring MRI infrastructure.

Demand -Drivers, Challenges, and Opportunities

Market Demand Drivers:

  • Increased Demand for Personalized Medicine

The growing demand for personalized medicine is rapidly driving the evolution of the image-guided drug delivery market, as it emphasizes the necessity for precise, targeted therapies tailored to individual patient profiles. In fields such as oncology and neurology, personalized medicine seeks to adapt treatments based on genetic and disease-specific characteristics, ensuring the most effective outcomes with minimal side effects. Image-guided drug delivery technologies play a pivotal role in this transformation by enabling accurate, localized targeting of medications to specific body regions, thereby enhancing the precision of therapeutic interventions. A 2024 study published in Pharmacological Research, titled "Biologics, Theranostics, and Personalized Medicine in Drug Delivery Systems," underscored the role of image-guided drug delivery in the realm of theranostics, a critical component of personalized medicine. This approach utilizes advanced imaging technologies to precisely direct and monitor therapeutics, ensuring accurate drug localization at targeted disease sites.

By minimizing off-target effects, this technique significantly enhances therapeutic outcomes. Moreover, the ability to adjust treatment in real-time optimizes drug delivery, ensuring that the right dosage reaches the right location. This precision is especially impactful in areas such as prostate cancer and neurodegenerative diseases, where accurate drug targeting can markedly improve patient outcomes.Some of the other driving factors include:

  • Rising Prevalence of Chronic Diseases

Note: All of the above factors will be evaluated in detail in the report.

Market Restraints:

  • High Acquisition Cost of the Instruments

The high cost of equipment for image-guided drug delivery presents a substantial barrier to the widespread adoption and market growth of this innovative technology, especially in low- and middle-income countries. These systems rely heavily on advanced imaging technologies such as MRI, CT, and fluoroscopy, which are essential for precise navigation during surgeries and drug delivery. However, the financial burden of these technologies is considerable. For instance, MRI machines can cost between $130,000 and $700,000, with additional ongoing expenses for maintenance, software updates, and specialized personnel training. The combination of these high upfront costs and continuous operational expenses creates a significant hurdle for hospitals, particularly in resource-constrained settings, making it difficult to justify the investment when healthcare budgets are limited.

As a result, this financial barrier not only limits the adoption of image-guided drug delivery systems in clinical environments but also hinders the overall expansion of the market. Smaller healthcare providers in emerging economies, where budgets are stretched thin, often cannot afford to invest in such technology, which may be perceived as non-essential in comparison to other immediate healthcare needs. This leads to a concentration of image-guided drug delivery technology in a small number of well-funded hospitals, restricting its broader application and diminishing its potential impact on patient care in underserved regions. Consequently, patients in these areas miss out on the benefits of more precise, targeted drug delivery, which is particularly valuable in cancer treatment and other specialized medical procedures requiring high levels of accuracy.

Market Opportunities:

  • Integration of Artificial Intelligence in Image-Guided Drug Delivery

The integration of Artificial Intelligence (AI) with image-guided drug delivery systems has emerged as a transformative advancement in cancer therapy, offering promising improvements in the accuracy, precision, and efficiency of drug delivery and monitoring. AI accelerates the process of image analysis, enabling the identification of subtle patterns within medical scans that optimize drug delivery to tumor sites. This innovation allows clinicians to target tumors with unprecedented precision, ensuring that the right amount of drug reaches the tumor while minimizing exposure to healthy tissue. Real-time monitoring, a critical component of personalized cancer care, is significantly enhanced through AI's ability to continuously track the behavior of drugs and nanoparticles within the body. AI algorithms monitor drug distribution and adjust the delivery process dynamically, ensuring better targeting of tumor cells. By providing this level of monitoring, AI contributes to improved treatment precision and outcomes, offering clinicians the tools necessary for more informed decision-making. AI's impact extends beyond the enhancement of imaging and monitoring to the personalization of treatment plans.

Market Trends:

Integration of Imaging with Targeted Drug Delivery

The integration of imaging with targeted drug delivery is a pivotal trend in modern medicine, fundamentally reshaping therapeutic approaches in both neurology and oncology. This paradigm shift is driven by a convergence of key developments, including significant regulatory milestones, growing clinical adoption, the launch of innovative new devices, and robust market momentum. This convergence is profoundly impacting the image-guided drug delivery market, transforming it from a niche, research-focused field into a rapidly expanding sector for mainstream clinical applications. This shift is fueled by the FDA's De Novo clearance of devices such as ClearPoint Neuro's SmartFlow Neuro Cannula, which validates a clear regulatory pathway for similar technologies, thereby reducing risk for investors and accelerating commercialization. On a clinical level, the use of real-time imaging and specialized catheters allows for unprecedented precision, ensuring a higher concentration of the therapeutic agent reaches the target site while sparing healthy tissue.

This not only improves treatment efficacy and reduces toxicity but also creates standardized, repeatable workflows that are more efficient and cost-effective for hospitals. The market is seeing a surge of new, purpose-built devices such as RenovoRx's RenovoCath and TriSalus Life Sciences' TriNav FLX, which are driving high-growth segments in targeted oncology and CNS delivery. Ultimately, the convergence of specialized delivery devices and image-guided navigation is creating a new standard of care, leading to reduced complications, higher procedure volumes, and improved patient outcomes in these critical therapeutic areas.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in Image-Guided Drug Delivery, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new Image-Guided Drug Delivery

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2023. The market size has been estimated for FY2024 and projected for the period FY2025-FY2035.
  • The scope of this report has been carefully derived based on extensive interactions with experts and stakeholders across leading companies and research institutions worldwide. This report provides a comprehensive market analysis of robotics and non-robotics within the Image-Guided Drug Delivery market.
  • Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available Image-Guided Drug Delivery products. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in Image-Guided Drug Delivery, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding the competitive landscape and business model
  • Current and proposed production values of a product by market players
  • Validation of the numbers of the different segments of the market in focus
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • Segmentations and percentage shares
  • Data for market value
  • Key industry trends of the top players of the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Key players in the image-guided drug delivery market include global medical device and imaging companies offering a broad range of drug delivery systems and image-guided platforms for oncology and neurology. Established firms such as ClearPoint Neuro, Inc., Koninklijke Philips N.V., and GE HealthCare dominate with portfolios spanning MRI-guided navigation, infusion cannulae, and vessel-mapping software integrated into interventional oncology and CNS therapies.

Innovators are developing multiport catheters, pressure-enabled infusion systems, and AI-assisted navigation software to improve delivery accuracy and therapeutic outcomes. Companies like TriSalus Life Sciences and RenovoRx are pioneering catheter-based oncology platforms, while AiM Medical Robotics and others are advancing MRI-compatible surgical robots for neurosurgical delivery. Emerging players, including Neurochase and Infuseon Therapeutics, are introducing novel convection-enhanced delivery systems for direct brain infusion.

Start-ups and regional firms are also contributing with cost-effective infusion technologies, portable navigation tools, and specialized drug-device combinations targeting unmet needs in emerging markets. Collectively, these companies are driving innovation, expanding clinical access, and establishing image-guided drug delivery as a cornerstone of precision-guided, minimally invasive therapeutic delivery.

Some prominent names established in this market are:

  • ClearPoint Neuro, Inc.
  • TriSalus Life Sciences, Inc.
  • GE Healthcare
  • Koninklijke Philips N.V.
  • RenovoRx Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

  • 1.1 Competitive Landscape
  • 1.2 Industry Outlook
    • 1.2.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
    • 1.2.2 Market Trends
      • 1.2.2.1 Integration of Imaging with Targeted Drug Delivery
    • 1.2.3 Advancements in Image-Guided Drug Delivery
    • 1.2.4 Future Direction and Emerging Technologies in Image-Guided Drug Delivery
  • 1.3 Market Dynamics
    • 1.3.1 Impact Analysis
    • 1.3.2 Market Driver
      • 1.3.2.1 Increased Demand for Personalized Medicine
      • 1.3.2.2 Rising Prevalence of Chronic Diseases
      • 1.3.2.3 Technological Advancements in Image-Guided Drug Delivery
    • 1.3.3 Market Restraint
      • 1.3.3.1 High Acquisition Cost of the Instruments
    • 1.3.4 Market Opportunity
      • 1.3.4.1 Integration of Artificial Intelligence in Image-Guided Drug Delivery

2 Technology

  • 2.1 Overview
  • 2.2 Drug Delivery Systems
  • 2.3 Image-Guided Platforms

3 Application

  • 3.1 Overview
  • 3.2 Oncology
  • 3.3 Neurology
  • 3.4 Others

4 End User

  • 4.1 Overview
  • 4.2 Hospitals
  • 4.3 Research Institutes and Universities
  • 4.4 Pharmaceutical and Biotechnology Companies
  • 4.5 Contract Research Organizations (CROs)

5 Region

  • 5.1 Regional Summary
  • 5.2 North America
    • 5.2.1 Regional Overview
    • 5.2.2 Driving Factors for Market Growth
    • 5.2.3 Factors Challenging the Market
    • 5.2.4 By Technology Type
    • 5.2.5 By Application
    • 5.2.6 By End User
    • 5.2.7 By Country
      • 5.2.7.1 U.S.
    • 5.2.8 By Technology Type
    • 5.2.9 By Application
    • 5.2.10 By End User
      • 5.2.10.1 Canada
    • 5.2.11 By Technology Type
    • 5.2.12 By Application
    • 5.2.13 By End User
  • 5.3 Europe
    • 5.3.1 Regional Overview
    • 5.3.2 Driving Factors for Market Growth
    • 5.3.3 Factors Challenging the Market
    • 5.3.4 By Technology Type
    • 5.3.5 By Application
    • 5.3.6 By End User
    • 5.3.7 By Country
      • 5.3.7.1 U.K.
    • 5.3.8 By Technology Type
    • 5.3.9 By Application
    • 5.3.10 By End User
      • 5.3.10.1 Germany
    • 5.3.11 By Technology Type
    • 5.3.12 By Application
    • 5.3.13 By End User
      • 5.3.13.1 France
    • 5.3.14 By Technology Type
    • 5.3.15 By Application
    • 5.3.16 By End User
      • 5.3.16.1 Italy
    • 5.3.17 By Technology Type
    • 5.3.18 By Application
    • 5.3.19 By End User
      • 5.3.19.1 Spain
    • 5.3.20 By Technology Type
    • 5.3.21 By Application
    • 5.3.22 By End User
      • 5.3.22.1 Rest-of-Europe
    • 5.3.23 By Technology Type
    • 5.3.24 By Application
    • 5.3.25 By End User
  • 5.4 Asia-Pacific
    • 5.4.1 Regional Overview
    • 5.4.2 Driving Factors for Market Growth
    • 5.4.3 Factors Challenging the Market
    • 5.4.4 By Technology Type
    • 5.4.5 By Application
    • 5.4.6 By End User
    • 5.4.7 By Country
      • 5.4.7.1 Japan
    • 5.4.8 By Technology Type
    • 5.4.9 By Application
    • 5.4.10 By End User
      • 5.4.10.1 China
    • 5.4.11 By Technology Type
    • 5.4.12 By Application
    • 5.4.13 By End User
      • 5.4.13.1 India
    • 5.4.14 By Technology Type
    • 5.4.15 By Application
    • 5.4.16 By End User
      • 5.4.16.1 Australia
    • 5.4.17 By Technology Type
    • 5.4.18 By Application
    • 5.4.19 By End User
      • 5.4.19.1 South Korea
    • 5.4.20 By Technology Type
    • 5.4.21 By Application
    • 5.4.22 By End User
      • 5.4.22.1 Rest-of-Asia-Pacific
    • 5.4.23 By Technology Type
    • 5.4.24 By Application
    • 5.4.25 By End User
  • 5.5 Rest-of-the-World
    • 5.5.1 Regional Overview
    • 5.5.2 Driving Factors for Market Growth
    • 5.5.3 Factors Challenging the Market
    • 5.5.4 By Technology Type
    • 5.5.5 By Application
    • 5.5.6 By End User
    • 5.5.7 Latin America
      • 5.5.7.1 Regional Overview
      • 5.5.7.2 Driving Factors for Market Growth
      • 5.5.7.3 Factors Challenging the Market
    • 5.5.8 Middle East and Africa
      • 5.5.8.1 Regional Overview
      • 5.5.8.2 Driving Factors for Market Growth
      • 5.5.8.3 Factors Challenging the Market
    • 5.5.9 Rest-of-the-World Country Overview

6 Markets - Company Profiles

  • 6.1 Company Profiles
    • 6.1.1 ClearPoint Neuro, Inc.
      • 6.1.1.1 Overview
      • 6.1.1.2 Top Products/Product Portfolio
      • 6.1.1.3 Top Competitors
      • 6.1.1.4 Target Customers
      • 6.1.1.5 Key Personnel
      • 6.1.1.6 Analyst View
      • 6.1.1.7 ClearPoint Neuro, Inc., Revenue ($Thousand), 2022-2024
    • 6.1.2 AiM Medical Robotics
      • 6.1.2.1 Overview
      • 6.1.2.2 Pipeline Product Portfolio
      • 6.1.2.3 Top Competitors
      • 6.1.2.4 Target Customers
      • 6.1.2.5 Key Personnel
      • 6.1.2.6 Analyst View
    • 6.1.3 TriSalus Life Sciences
      • 6.1.3.1 Overview
      • 6.1.3.2 Top Products/Product Portfolio
      • 6.1.3.3 Top Competitors
      • 6.1.3.4 Target Customers
      • 6.1.3.5 Key Personnel
      • 6.1.3.6 Analyst View
      • 6.1.3.7 TriSalus Life Sciences, Revenue ($Thousand), 2022-2024
    • 6.1.4 RenovoRx Inc.
      • 6.1.4.1 Overview
      • 6.1.4.2 Top Products/Product Portfolio
      • 6.1.4.3 Top Competitors
      • 6.1.4.4 Target Customers
      • 6.1.4.5 Key Personnel
      • 6.1.4.6 Analyst View
      • 6.1.4.7 RenovoRx Inc., Revenue ($Thousand), 2022-2024
    • 6.1.5 Renishaw plc.
      • 6.1.5.1 Overview
      • 6.1.5.2 Pipeline Product Portfolio
      • 6.1.5.3 Top Competitors
      • 6.1.5.4 Target Customers
      • 6.1.5.5 Key Personnel
      • 6.1.5.6 Analyst View
      • 6.1.5.7 Renishaw plc., Revenue ($Million), 2022-2024
    • 6.1.6 Occam Design
      • 6.1.6.1 Overview
      • 6.1.6.2 Pipeline Product Portfolio
      • 6.1.6.3 Top Competitors
      • 6.1.6.4 Target Customers
      • 6.1.6.5 Key Personnel
      • 6.1.6.6 Analyst View
    • 6.1.7 Infuseon Therapeutics Inc
      • 6.1.7.1 Overview
      • 6.1.7.2 Pipeline Product Portfolio
      • 6.1.7.3 Top Competitors
      • 6.1.7.4 Target Customers
      • 6.1.7.5 Key Personnel
      • 6.1.7.6 Analyst View
    • 6.1.8 Neurochase
      • 6.1.8.1 Overview
      • 6.1.8.2 Pipeline Product Portfolio
      • 6.1.8.3 Top Competitors
      • 6.1.8.4 Target Customers
      • 6.1.8.5 Key Personnel
      • 6.1.8.6 Analyst View
    • 6.1.9 GE HealthCare
      • 6.1.9.1 Overview
      • 6.1.9.2 Top Products/Product Portfolio
      • 6.1.9.3 Top Competitors
      • 6.1.9.4 Target Customers
      • 6.1.9.5 Key Personnel
      • 6.1.9.6 Analyst View
      • 6.1.9.7 GE HealthCare, Revenue ($Million), 2022-2024
    • 6.1.10 Koninklijke Philips N.V.
      • 6.1.10.1 Overview
      • 6.1.10.2 Top Products/Product Portfolio
      • 6.1.10.3 Top Competitors
      • 6.1.10.4 Target Customers
      • 6.1.10.5 Key Personnel
      • 6.1.10.6 Analyst View

7 Research Methodology

  • 7.1 Data Sources
    • 7.1.1 Primary Data Sources
    • 7.1.2 Secondary Data Sources
    • 7.1.3 Data Triangulation
  • 7.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Image-Guided Drug Delivery Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure 2: Global Image-Guided Drug Delivery Market, 2024 and 2035
  • Figure 3: Top 9 Countries, Global Image-Guided Drug Delivery Market, $Million, 2024
  • Figure 4: Global Image-Guided Drug Delivery Market Snapshot
  • Figure 5: Global Image-Guided Drug Delivery Market, $Million, 2024 and 2035
  • Figure 6: Global Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024, 2030, and 2035
  • Figure 7: Global Image-Guided Drug Delivery Market (by Application), $Million, 2024, 2030, and 2035
  • Figure 8: Global Image-Guided Drug Delivery Market (by End User), $Million, 2024, 2030, and 2035
  • Figure 9: Image-Guided Drug Delivery Market Segmentation
  • Figure 10: Global Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024, 2030, and 2035
  • Figure 11: Global Image-Guided Drug Delivery Market (Drug Delivery Systems), $Million, 2024-2035
  • Figure 12: Global Image-Guided Drug Delivery Market (Image-Guided Platforms), $Million, 2024-2035
  • Figure 13: Global Image-Guided Drug Delivery Market (by Application), $Million, 2024, 2030, and 2035
  • Figure 14: Global Image-Guided Drug Delivery Market (Oncology), $Million, 2024-2035
  • Figure 15: Global Image-Guided Drug Delivery Market (Neurology), $Million, 2024-2035
  • Figure 16: Global Image-Guided Drug Delivery Market (Others), $Million, 2024-2035
  • Figure 17: Global Image-Guided Drug Delivery Market (by End User), $Million, 2024, 2030, and 2035
  • Figure 18: Global Image-Guided Drug Delivery Market (Hospitals), $Million, 2024-2035
  • Figure 19: Global Image-Guided Drug Delivery Market (Research Institutes and Universities), $Million, 2024-2035
  • Figure 20: Global Image-Guided Drug Delivery Market (Pharmaceutical and Biotechnology Companies), $Million, 2024-2035
  • Figure 21: Global Image-Guided Drug Delivery Market (Contract Research Organizations (CROs), $Million, 2024-2035
  • Figure 22: U.S. Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 23: Canada Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 24: U.K. Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 25: Germany Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 26: France Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 27: Italy Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 28: Spain Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 29: Rest-of-Europe Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 30: Japan Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 31: China Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 32: India Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 33: Australia Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 34: South Korea Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 35: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 36: Data Triangulation
  • Figure 37: Top-Down and Bottom-Up Approach
  • Figure 38: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Image-Guided Drug Delivery Market (by Region), $Million, 2024-2035
  • Table 3: North America Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 4: North America Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 5: North America Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 6: U.S. Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 7: U.S. Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 8: U.S. Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 9: Canada Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 10: Canada Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 11: Canada Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 12: Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 13: Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 14: Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 15: U.K. Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 16: U.K. Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 17: U.K. Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 18: Germany Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 19: Germany Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 20: Germany Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 21: France Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 22: France Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 23: France Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 24: Italy Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 25: Italy Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 26: Italy Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 27: Spain Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 28: Spain Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 29: Spain Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 30: Rest-of-Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 31: Rest-of-Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 32: Rest-of-Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 33: Asia-Pacific Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 34: Asia-Pacific Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 35: Asia-Pacific Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 36: Japan Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 37: Japan Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 38: Japan Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 39: China Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 40: China Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 41: China Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 42: India Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 43: India Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 44: India Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 45: Australia Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 46: Australia Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 47: Australia Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 48: South Korea Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 49: South Korea Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 50: South Korea Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 51: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 52: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 53: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 54: Rest-of-the-World Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 55: Rest-of-the-World Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 56: Rest-of-the-World Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035